Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Patient Selection

AL Aurelie Lenglet
MR Mohamad Ali Rahali
FS François-Ludovic Sauvage
SL Sophie Liabeuf
GC Gabriel Choukroun
ME Marie Essig
SB Souleiman El Balkhi
ZM Ziad A. Massy
ask Ask a question
Favorite

This was the secondary analysis of the NICOREN trial data [7]. The trial included 100 patients undergoing long-term hemodialysis treated with either sevelamer-HCl or nicotinamide for 24 weeks. The patients were dialyzed three times per week for 3.5–5.0 h. The study was performed in 18 hemodialysis centers across France. All patients gave their informed written consent to the initial and subsequent biochemical analyses. The protocol was approved by a local investigational review board (CPP Nord Ouest II, Amiens, France; reference: 2008-004673-17) and implemented in accordance with the ethical principles of the Declaration of Helsinki (ClinicalTrials.gov registration number: NCT01011699).

Copyright and License information: The Author(s) ©2021
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A